Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma

被引：6

作者：

Du, Wei ^{[1
]}

Shi, Xiangyu ^{[2
]}

Fang, Qigen ^{[1
]}

Zhang, Xu ^{[1
]}

Liu, Shanting ^{[1
]}

机构：

[1] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Head Neck & Thyroid, Zhengzhou, Peoples R China

[2] Peoples Hosp Changshou Dist, Dept Breast & Thyroid Surg, Chongqing, Peoples R China

来源：

FRONTIERS IN ENDOCRINOLOGY | 2022年 / 13卷

关键词：

differentiated thyroid carcinoma; apatinib; radioiodine refractory differentiated thyroid carcinoma; targeted treatment; drug efficacy; DOUBLE-BLIND; PHASE-III; CANCER; LENVATINIB; PLACEBO;

D O I：

10.3389/fendo.2022.768028

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ObjectivesOur aim was to describe our experience in using apatinib as treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC). MethodsForty-seven patients undergoing apatinib treatment for RAIR-DTC were prospectively enrolled in this study. The study endpoints were objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and rate of adverse events. ResultsNo patients achieved complete response, while 36 (76.6%) and 8 (17.0%) patients achieved partial response and stable disease, respectively. The ORR and DCR were 76.6% and 93.6%, respectively. The median PFS and OS were 18 and 59 months, respectively. A total of 91 adverse events occurred, of which 21 were graded as grade 3 or higher. There were no drug-related deaths. ConclusionsApatinib has distinct anti-RAIR-DTC efficacy in terms of ORR, PFS, and OS and has a favorable safety profile. It is a feasible treatment option for RAIR-DTC.

引用

页数：6

共 25 条

[1] Prognostic role of the lymphocyte-to-monocyte ratio for clinical outcomes of patients with progressive radioiodine-refractory differentiated thyroid carcinoma treated by sorafenib [J].

Ahn, Jonghwa ;

Song, Eyun ;

Kim, Won Gu ;

Kim, Tae Yong ;

Kim, Won Bae ;

Shong, Young Kee ;

Jeon, Min Ji .

CLINICAL ENDOCRINOLOGY, 2020, 92 (01) :71-76

[2] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J].

Brose, Marcia S. ;

Nutting, Christopher M. ;

Jarzab, Barbara ;

Elisei, Rossella ;

Siena, Salvatore ;

Bastholt, Lars ;

de la Fouchardiere, Christelle ;

Pacini, Furio ;

Paschke, Ralf ;

Shong, Young Kee ;

Sherman, Steven I. ;

Smit, Johannes W. A. ;

Chung, John ;

Kappeler, Christian ;

Pena, Carol ;

Molnar, Istvan ;

Schlumberger, Martin J. .

LANCET, 2014, 384 (9940) :319-328

[3] The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF® network review [J].

de la Fouchardiere, Christelle ;

Alghuzlan, Abir ;

Bardet, Stephane ;

Borget, Isabelle ;

Chazot, Francoise Borson ;

Do Cao, Christine ;

Godbert, Yann ;

Leenhardt, Laurence ;

Zerdoud, Slimane ;

Leboulleux, Sophie .

BULLETIN DU CANCER, 2019, 106 (09) :812-819

[4] Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline [J].

Fakhry, Carole ;

Lacchetti, Christina ;

Rooper, Lisa M. ;

Jordan, Richard C. ;

Rischin, Danny ;

Sturgis, Erich M. ;

Bell, Diana ;

Lingen, Mark W. ;

Harichand-Herdt, Seema ;

Thibo, John ;

Zevallos, Jose ;

Perez-Ordonez, Bayardo .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (31) :3152-+

[5] 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J].

Haugen, Bryan R. ;

Alexander, Erik K. ;

Bible, Keith C. ;

Doherty, Gerard M. ;

Mandel, Susan J. ;

Nikiforov, Yuri E. ;

Pacini, Furio ;

Randolph, Gregory W. ;

Sawka, Anna M. ;

Schlumberger, Martin ;

Schuff, Kathryn G. ;

Sherman, Steven I. ;

Sosa, Julie Ann ;

Steward, David L. ;

Tuttle, R. Michael ;

Wartofsky, Leonard .

THYROID, 2016, 26 (01) :1-133

[6]

Hussen Bashdar Mahmud, 2021, FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, V9, DOI [DOI 10.3389/FCELL.2021.689992, 10.3389/fcell.2021.689992]

[7] Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review [J].

Jones, Heidi ;

Green, Victoria ;

England, James ;

Greenman, John .

FUTURE SCIENCE OA, 2021, 7 (07)

[8] Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer [J].

Juweid, Malik E. ;

Tulchinsky, Mark ;

Mismar, Ayman ;

Momani, Munther ;

Zayed, Ayman A. ;

Al Hawari, Hussam ;

Albsoul, Nader ;

Mottaghy, Felix M. .

INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (09) :2345-2354

[9] Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer [J].

Koehler, Viktoria Florentine ;

Berg, Elke ;

Adam, Pia ;

Weber, Gian-Luca ;

Pfestroff, Andreas ;

Luster, Markus ;

Kutsch, Jana Maria ;

Lapa, Constantin ;

Sandner, Benjamin ;

Rayes, Nada ;

Fuss, Carmina Teresa ;

Kreissl, Michael C. ;

Hoster, Eva ;

Allelein, Stephanie ;

Schott, Matthias ;

Todica, Andrei ;

Fassnacht, Martin ;

Kroiss, Matthias ;

Spitzweg, Christine .

THYROID, 2021, 31 (10) :1531-1541

[10] Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas [J].

Li, Genpeng ;

Lei, Jianyong ;

Song, Linlin ;

Jiang, Ke ;

Wei, Tao ;

Li, Zhihui ;

Gong, Rixiang ;

Zhu, Jingqiang .

CANCER MEDICINE, 2018, 7 (11) :5448-5456

← 1 2 3 →